Ren Song

Ren Song is a Principal Scientist at Allogene Therapeutics since February 2021, having previously held the position of Senior Scientist at the same company. Prior to this role, Ren Song served as a Postdoctoral Researcher at Stanford University School of Medicine from July 2016 to January 2021, focusing on enhancing AAV viral vectors for gene therapy delivery across the human blood-brain barrier under the guidance of Professor Mark A. Kay. Ren Song earned a Doctor of Philosophy (PhD) in Molecular Biology from Princeton University, where studies were conducted from 2010 to 2016, and holds a Bachelor of Science (BS) in Life Science and Biotechnology from Wuhan University.